A New Fluidized Bed Bioreactor Based on Diversion-Type Microcapsule Suspension for Bioartificial Liver Systems
Open accessThe DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.
Abstract
A fluidized bed bioreactor containing encapsulated hepatocytes may be a valuable alternative to a hollow fiber bioreactor for achieving the improved mass transfer and scale-up potential necessary for clinical use. However, a conventional fluidized bed bioreactor (FBB) operating under high perfusion velocity is incapable of providing the desired performance due to the resulting damage to cell-containing microcapsules and large void volume. In this study, we developed a novel diversion-type microcapsule-suspension fluidized bed bioreactor (DMFBB). The void volume in the bioreactor and stability of alginate/chitosan microcapsules were investigated under different flow rates. Cell viability, synthesis and metabolism functions, and expression of metabolizing enzymes at transcriptional levels in an encapsulated hepatocyte line (C3A cells) were determined. The void volume was significantly less in the novel bioreactor than in the conventional FBB. In addition, the microcapsules were less damaged in the DMFBB during the fluidization process as reflected by the results for microcapsule retention rates, swelling, and breakage. Encapsulated C3A cells exhibited greater viability and CYP1A2 and CYP3A4 activity in the DMFBB than in the FBB, although the increases in albumin and urea synthesis were less prominent. The transcription levels of several CYP450-related genes and an albumin-related gene were dramatically greater in cells in the DMFBB than in those in the FBB. Taken together, our results suggest that the DMFBB is a promising alternative for the design of a bioartificial liver system based on a fluidized bed bioreactor with encapsulated hepatocytes for treating patients with acute hepatic failure or other severe liver diseases.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Microscale culture of human liver cells for drug development
Khetani, S. R., & Bhatia, S. N. (2008) · Nature Biotechnology · doi:10.1038/nbt1361 · Cited by 1,219 · cited 1×
“Several classes of CYP450 phase I and phase II enzymes and specific proteins [22] were selected to test whether the DMFBB could improve the transcription of metabolism-related genes in hepatocytes by real-time PCR (Fig 6).”
MethodBioreactor design for tissue engineering
Pörtner, R., Nagel-Heyer, S., Goepfert, C., Adamietz, P., & Meenen, N. M. (2005) · Journal of Bioscience and Bioengineering · doi:10.1263/jbb.100.235 · Cited by 305
Richert, L., Liguori, M. J., Abadie, C., Heyd, B., Mantion, G., Halkic, N., & Waring, J. F. (2006) · Drug Metabolism and Disposition · doi:10.1124/dmd.105.007708 · Cited by 136
Cited by
A decade of progress in liver regenerative medicine
Zhang, J., Zhao, X., Liang, L., Li, J., Demirci, U., & Wang, S. (2018) · Biomaterials · doi:10.1016/j.biomaterials.2017.11.027 · Cited by 111
“2 3 Apart from liver tissue engineering, other liver regenerative medicine-based strategies such as 4 bioartifical liver (BAL) devices [15, 16] and liver-on-a-chip platforms [17, 18] have been 5 developed to mainly provide extracorporeal support [19] and pharmacological testing [20, 21], 6 respectively.”
BackgroundGarnier, D., Li, R., Delbos, F., Fourrier, A., Collet, C., Guguen-Guillouzo, C., Chesné, C., & Nguyen, T. H. (2018) · Scientific Reports · doi:10.1038/s41598-018-26584-1 · Cited by 71
Bioartificial livers: a review of their design and manufacture
Tuerxun, K., He, J., Ibrahim, I., Yusupu, Z., Yasheng, A., Xu, Q., Tang, R., Aikebaier, A., Wu, Y., Tuerdi, M., et al. (2022) · Biofabrication · doi:10.1088/1758-5090/ac6e86 · Cited by 24
“Experiments showed that the void volume was significantly decreased and that the microcap-sules were less damaged in the optimized bioreactor [102].”
InfluentialStem Cell-Based Strategies: The Future Direction of Bioartificial Liver Development
Feng, L., Wang, Y., Fu, Y., Li, T., & He, G. (2024) · Stem Cell Reviews and Reports · doi:10.1007/s12015-023-10672-5 · Cited by 9
“B: Fluid-ized bed bioreactors and cell culture model diagram [194].”
Lu, J., Zhu, D., & Li, L. (2022) · The International Journal of Artificial Organs · doi:10.1177/03913988211066502 · Cited by 3
Self-citation
Metadata
- Authors
- Lu, J., Zhang, X., Li, J., Yu, L., Chen, E., Zhu, D., Zhang, Y., & Li, L.
- Venue
- PLOS ONE
- Publisher
- Public Library of Science (PLoS)
- Published
- 2016-02-03
- Volume
- 11
- Issue
- 2
- Pages
- e0147376
- ISSN
- 1932-6203 (ISSN-L)
- OpenAlex
- W2271917459
- Cited by
- 32
- References
- 3
- FWCI
- 3.32
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: A New Fluidized Bed Bioreactor Based on Diversion-Type Microcapsule Suspension for Bioartificial Liver Systems. https://app.cochat.ai/papers/10.1371/journal.pone.0147376
- The paper
- Lu, J., Zhang, X., Li, J., Yu, L., Chen, E., Zhu, D., Zhang, Y., & Li, L. (2016). A New Fluidized Bed Bioreactor Based on Diversion-Type Microcapsule Suspension for Bioartificial Liver Systems. PLOS ONE. https://doi.org/10.1371/journal.pone.0147376
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.